Ibandronate is a third-generation biphosphonate with recognized antiresorptive efficacy by several international, randomized, double-blind, controlled trials. These studies have not included patients from central america, to the best of our knowledge. Therefore, this open-label, uncontrolled study, was set out to assess the clinical effects of a 6-m treatment course with Ibandronate plus vitamine D and Calcium on bone mineral density and health-related quality of life.

Inclusion Criteria:

• Women with a diagnosis of osteoporosis of at-Risk
• Have a medical indication to receive Ibandronate+Vitamine D+Calcium

Exclusion Criteria:

• Osteoporosis due to secondary causes

Postmenopausal women with a diagnosis of osteoporosis o with a high risk of developing it in the near future.